Drug Shortage Report for OCTREOTIDE FOR INJECTABLE SUSPENSION

Last updated on 2025-03-27 History
Report ID 247309
Drug Identification Number 02503778
Brand name OCTREOTIDE FOR INJECTABLE SUSPENSION
Common or Proper name OCTREOTIDE FOR INJ 20MG/VIAL-KIT
Company Name TEVA CANADA LIMITED
Market Status MARKETED
Active Ingredient(s) OCTREOTIDE
Strength(s) 20MG
Dosage form(s) POWDER FOR SUSPENSION, SUSTAINED-RELEASE KIT
Route of administration INTRAMUSCULAR
Packaging sizes (GTIN)

Click here to see a list of all reports for this drug.

(See additional packaging sizes)
Additional packaging sizes KIT
ATC code H01CB
ATC description HYPOTHALAMIC HORMONES
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2025-01-07
Estimated end date 2025-05-20
Actual end date
Shortage status Actual shortage
Updated date 2025-03-27
Company comments Product is on allocation
Health Canada comments
Tier 3 Status No
Contact Address 30 NOVOPHARM COURT
TORONTO, ONTARIO
CANADA M1B 2K9
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v6 2025-03-27 French Compare
v5 2025-03-27 English Compare
v4 2025-01-30 French Compare
v3 2025-01-30 English Compare
v2 2025-01-09 French Compare
v1 2025-01-09 English Compare

Showing 1 to 6 of 6